Tolerability of Inhaled Hypertonic Saline in Infants With Cystic Fibrosis (ISIS Pilot)

CF Therapeutics Development Network Coordinating Center

Status

Completed

Conditions

Cystic Fibrosis

Treatments

Drug: inhaled 7% hypertonic saline (HS)

Study type

Interventional

Funder types

Other

NETWORK

Identifiers

NCT00546663

ISIS001

Details and patient eligibility

About

This is an open-label pilot study of the safety and tolerability of 7% hypertonic saline inhaled twice daily for 14 days in infants with CF, 12 to 30 months of age.

Full description

The efficacy and safety of hypertonic saline (HS) in CF patients over 6 years of age has been demonstrated in clinical trials of 2 to 48 weeks' duration. Based on these results, a large randomized, placebo-controlled trial of the efficacy and safety of 7% HS administered twice daily for 48 weeks to infants with CF, 4 to 15 months of age at enrollment, is planned (the Infant Study of Inhaled Saline (ISIS) trial). It is anticipated that 150 infants at up to 16 sites will be enrolled in the ISIS trial.

To date, the only evaluations of the safety of HS in infants with CF have been small single-dose studies. There has been no evaluation of the tolerability of chronic HS administration. The goal of this study is to assess the safety and tolerability of exposure to 14 days of 7% HS administered twice daily in infants with CF, prior to enrolling subjects in the planned large, randomized, controlled trial. Conduct of this study will provide evidence for the tolerability of chronic HS administration in infants with CF and estimates of the proportion of infants who do not tolerate chronic HS treatment. The results will be used to establish the appropriate measures of tolerability at enrollment in the ISIS trial, and to refine sample size estimates to account for withdrawal due to intolerance of HS.

Enrollment

19 patients

Sex

All

Ages

12 to 30 months old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosis of CF as defined by one or more clinical features of CF and a documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis test or a genotype showing two well characterized disease causing mutations
Informed consent by parent or legal guardian
12-30 months of age at enrollment

Exclusion criteria

Wheezing at the baseline evaluation at the enrollment visit
Oxygen saturation < 95 % at the baseline evaluation at the enrollment visit
Acute intercurrent respiratory infection, defined as an increase in cough, wheezing, or respiratory rate, or new rhinorrhea, nasal congestion or rhinorrhea, with onset in the week preceding the enrollment visit
Investigational drug use within 30 days prior to the enrollment visit
Known intolerance of albuterol
Current enrollment in a therapeutic clinical trial
Condition or situation which, in the opinion of the investigator, would affect the ability of the patient or family to complete study procedures